Physician profile
Abraham Mathai
NPI 1215468483
$914.28
in general payments reported to CMS, 2019-2025
23 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.63 · 2022: $223 · 2023: $195 · 2024: $117 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.31 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $101.33 | 2022-2025 | Breztri, Farxiga |
| Abbvie INC. | $96.96 | 2023-2025 | |
| Lilly USA, LLC | $80.95 | 2022-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $77.22 | 2023-2025 | Ozempic |
| Exact Sciences Corporation | $65.93 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $62.74 | 2025 | Korlym |
| Mannkind Corporation | $59.40 | 2022 | |
| Glaxosmithkline, LLC. | $42.41 | 2023-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $41.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.61 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.18 | 2021 | |
| Horizon Therapeutics Plc | $23.55 | 2021 | |
| Mylan Specialty L.P. | $23.51 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.39 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $22.93 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $21.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.21 | 2022 | |
| Bausch Health US, LLC | $18.89 | 2022 | |
| Pfizer INC. | $18.71 | 2025 | |
| Dexcom, INC. | $18.18 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $14.76 | 2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $14.71 | 2021 | |
| Amgen INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.